But is prophylaxis extension the best approach to preventing late-onset cytomegalovirus disease? Humar, A. et al. The IMPACT Study: Valganciclovir prophylaxis for until 200 days post-transplant in ...

Cytomegalovirus (CMV) is a ubiquitous herpesvirus that persists indefinitely after primary infection, usually in a latent form in various tissues (e.g., kidney, liver, lung). [1] One percent of ...

After congenital, perinatal, or early postnatal infection, the virus may linger for years in body fluids. Sources of CMV infection in transplant recipients include latent reactivation, donor ...

Laboratory workup of 26 others detected nonclinical CMV infection at a median of 32 days after surgery ... with negative CMV serology before transplantation were less likely to develop coronary ...

CMV is one of the most common and serious post-transplant infections with an estimated incidence rate of between 16% and 56% in solid organ transplants, and 30% to 70% in HSCT procedures.

Four were due to cytomegalovirus ... dying without demonstrable infection lived for less than twenty-four days after transplant. All the patients with triple infections, on the other hand ...

More than 55% of transplant recipients with refractory CMV infections achieved confirmed viral clearance with Takeda's drug, compared to around 24% of those on conventional antivirals.

I wanted to learn more so I spoke to Dr Andy Charlton, a consultant in haematology and transfusion medicine at NHS Blood and Transplant ... soon after birth by a transfusion of CMV-free blood.